Propanc Biopharma, Inc.
PPCB
Jodie situation report
Propanc Biopharma, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 4 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 18 directly disclosed connections are confirming.
- PPCB's market-adjusted activity becomes unusual and at least one connected name confirms.
Invalidation: The isolated read changes if PPCB's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind PPCB
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
COOTFiling-linked namepartnerSep 29, 2025 ▾
“The results discussed below are of the Company and its wholly-owned Australian subsidiary, Propanc PTY LTD.”
INCYIncyte CorporationpartnerSep 29, 2025 ▾
“rmerly, GlaxoSmithKline plc (Tesaro)), Gradalis, Inc., Incyte Corporation, MacroGenics, Inc., Oncotelic Therapeutics, Inc.”
KZIAFiling-linked namepartnerSep 29, 2025 ▾
“rmerly, GlaxoSmithKline plc (Tesaro)), Gradalis, Inc., Incyte Corporation, MacroGenics, Inc., Oncotelic Therapeutics, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 15 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
PPCB is currently a Early Follower in the organic co-movement group Utilities and Defense. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for PPCB; it is not active in the latest market snapshot.